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Background: Electroporation is a novel treatment technique utilizing electric pulses, traveling between two or more
electrodes, to ablate targeted tissue. The first in human studies have proven the safety of IRE for the ablation of renal
masses. However the efficacy of IRE through histopathological examination of an ablated renal tumour has not yet
been studied. Before progressing to a long-term IRE follow-up study it is vital to have pathological confirmation of the
efficacy of the technique. Furthermore, follow-up after IRE ablation requires a validated imaging modality. The primary
objectives of this study are the safety and the efficacy of IRE ablation of renal masses. The secondary objectives are
the efficacy of MRI and CEUS in the imaging of ablation result.
Methods/Design: 10 patients, age≥ 18 years, presenting with a solid enhancing mass, who are candidates for radical
nephrectomy will undergo IRE ablation 4 weeks prior to radical nephrectomy. MRI and CEUS imaging will be
performed at baseline, one week and four weeks post IRE. After radical nephrectomy, pathological examination will be
performed to evaluate IRE ablation success.
Discussion: The only way to truly assess short-term (4 weeks) ablation success is by histopathology of a resection
specimen. In our opinion this trial will provide essential knowledge on the safety and efficacy of IRE of renal masses,
guiding future research of this promising ablative technique.
Trial registration: Clinicaltrials.gov registration number NCT02298608.
Dutch Central Committee on Research Involving Human Subjects registration number NL44785.018.13
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The past two decades have shown a steady increase in
the incidence of small renal masses (SRM) up to 4 cm
[1,2]. Nephron sparing surgery, in the form of partial
nephrectomy, is considered to be the gold standard for
treatment of SRMs [3]. Currently thermal focal therapies
such as cryoablation and radiofrequency ablation (RFA)
are primarily recommended in patients who are poor
surgical candidates or have a genetic predisposition for
developing multiple tumours [4-6]. However, promising
long-term results combined with little or no loss in renal* Correspondence: p.g.wagstaff@amc.nl
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unless otherwise stated.function have created interest in thermal focal therapies
as a future treatment option for a broader range of
patients [7-10].
Focal treatment of kidney tumour requires precisely
dosed and accurate targeting of the tissue to be ablated
while preserving surrounding healthy tissue and vital
structures such as blood vessels, nerves, the renal col-
lecting system and neighbouring organs [11]. The un-
selective destruction of currently practiced thermal
ablation techniques can result in damage to vital struc-
tures in the vicinity of the tumour and undesired ex-
cessive ablation of normal parenchyma [12]. Thermal
ablation intensity can be impaired due to ‘heat sink’ in
the vicinity of large vessels and the renal collecting
system [4].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nique in which electric pulses, traveling between two or
more electrodes, are used to create ‘nanopores’ in the
cell membrane. These pores allow for molecules to pass
into the cell. The process can be temporary (reversible
electroporation, RE), however above a certain threshold
the ‘nanopores’ become permanent causing cell death
due to the inability to maintain homeostasis (irreversible
electroporation, IRE) [13-15]. It has been hypothesized
that IRE is not dependent on temperature and is there-
fore not influenced by ‘heat sink’ promising consistent
ablation results [11]. In theory IRE is defined to damage
of the cell membrane, sparing tissue architecture and
minimizing damage to blood vessels, nerves and the
renal collecting system [16]. Recent literature however,
has predicted [17] and measured [18,19] a large increase
of temperature in healthy porcine kidney using currently
practiced equipment and settings. As a result, it remains
unclear to which extent the thermal effect or the electro-
poration contribute to the IRE ablation effect. Histo-
pathology using viability staining of renal IRE lesions
shows a sharp demarcation between ablated and non-
ablated tissue allowing for precise targeting while spar-
ing the surrounding healthy tissue [20,21].
Animal trials have assessed the use of MRI and CT im-
aging for the intermediate follow-up of IRE lesions. Con-
trast enhanced CT imaging directly after IRE ablation of
porcine kidney showed a hypodense non-enhancing le-
sion, persisting at 1 week post IRE. At 3 weeks, 4 out of 6
IRE lesions had disappeared completely [22]. Thomson
et al. performed in human IRE in 10 renal tumours with
subsequent follow-up by CT imaging. At 3 months post
IRE incomplete ablation was diagnosed in 2 patients on
the basis of CT-imaging. However, the authors provide
little information on the imaging characteristics of the
residual lesion. MRI directly after IRE of porcine kidney
showed a localized oedema at the region of IRE ablation.
At 7 days after IRE a hypo-intense necrosis-like lesion in
the renal parenchyma at the region of IRE was visualised.
Finally, at 28 days a sharply delineated, non-intense, scar-
like lesion with cortical shrinkage and without contrast
enhancement was visualised [20]. These results provide
an insight in the use of imaging for the follow-up of renal
IRE. However, a study where follow-up imaging, specific-
ally assessment of ablation volume and residual enhan-
cing tumour, is correlated to histopathology of the
resected specimen has not yet been performed.
Procedural safety of renal IRE in humans has been
tested and confirmed [15]. The electric pulses adminis-
tered during IRE have the potential of causing cardiac
arrhythmias; by synchronising the IRE pulses with the
ECG this complication can be avoided [23]. In a study
by Pech et al., ablated tumours were resected directly
after IRE and they observed swelling of cells but noactual cell death. However, histological staining to assess
cell viability was not performed [15].
Before progressing to a long-term IRE follow-up study
it is vital to have pathological confirmation of the effi-
cacy of the technique. Furthermore, follow-up of IRE
ablation requires an accurate imaging modality. This
trial will investigate IRE ablation efficacy by correlating
3D histopathology of a resected IRE lesion with: 1) 3D
reconstructed imaging using MRI and contrast enhance
ultrasound (CEUS), and 2) the 3D predicted ablation
volume as provided by the manufacturer. The objectives
of the study are assessing the safety and efficacy of IRE
of renal masses (primary objectives), and assessing the
efficacy of MRI and CEUS for the initial evaluation and
short-term (4 weeks) follow-up of IRE lesions (secondary
objectives). This study conforms to the recommenda-
tions of the IDEAL Collaboration and can be categorised
as a phase 2A development trial [24].Methods/Design
Ethical consideration
The Institutional Review Board (IRB) of the Academic
Medical Center, Amsterdam, approved this study proto-
col (2013_219). The protocol has been registered with
The Dutch Central Committee on Research Involving
Human Subjects (NL44785.018.13) and is entered in the
clinicaltrials.gov database (NCT02298608). Potential can-
didates will receive the study information both verbally
and in writing. They will be granted at least one week to
decide on participation. Written informed consent is ac-
quired from all participants.Study design
This is a prospective, human, in-vivo study among 10
patients presenting with a solid renal mass, and candi-
dates for radical nephrectomy (RN). A study flowchart is
provided in Figure 1. Prior to the IRE procedure baseline
MRI and CEUS imaging will be acquired. Subsequently
the patients will undergo IRE ablation of their renal
mass. Follow-up at one and four weeks post IRE will be
performed using MRI and CEUS imaging. At these time
points procedure and device related adverse events (AE)
will be registered using the Common Terminology Cri-
teria for Adverse Events (CTCAE) version 4.0 guideline.
Four weeks after IRE the patients will undergo radical
nephrectomy after which pathological examination will
be performed to evaluate IRE ablation success. Core
biopsies are harvested before IRE ablation in order to
assure tumour differentiation in case of complete abla-
tion. Correlation between pathology and imaging will
reveal the efficacy of MRI and CEUS for the assessment
of IRE lesions.
Figure 1 Study design flowchart.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
○ Age≥ 18 years ○ Irreversible bleeding disorders
○ Solid enhancing mass on cross
sectional imaging
○ Inability to stop anticoagulation
therapy
○ Scheduled for open or
laparoscopic RN
○ Prev. cryoablation, RFA or PN
affected kidney
○ Signed informed consent ○ Anaesthesia Surgical Assignment
(ASA) cat. ≤ IV
○ ICD or pacemaker
○ Severe cardiovascular disease
Severe cardiovascular disease is defined as the diagnosis of myocardial
infarction, uncontrolled angina, significant ventricular arrhythmias, stroke or
severe cardiac failure (NYHA class ≥ III) within 6 months prior to inclusion.
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Primary objectives:
– To determine the efficacy of IRE ablation of renal
masses, measured by pathological examination of
the targeted tumour.
– To determine the safety of IRE ablation of renal
masses, by evaluating device and procedural adverse
events using CTCAE v4.0.
Secondary objectives:
– To evaluate the efficacy of MRI in the imaging of
ablation success, the extent of the ablation zone, one
and four weeks post IRE ablation.
– To evaluate the efficacy of CEUS in the imaging of
ablation success, the extent of the ablation zone, one
and four weeks post IRE ablation.
Population
Ten patients with a solid enhancing renal mass and sched-
uled for a radical nephrectomy will be enrolled in this
study. Eligible patients are over 18 years of age, and candi-
date for radical nephrectomy due to tumour size/stage, or
ESRD (stage 4 or 5), or the need for a pre-emptive trans-
plant kidney. The development of IRE is aimed at the
ablation of small renal masses (SRM). According to EAUand Dutch Association of Urology (NVU) protocol the
preferred treatment of a SRM in an otherwise functioning
kidney is partial nephrectomy (PN). Performing IRE abla-
tion in these cases might, however complicate a subse-
quent partial nephrectomy leading to impaired surgical
outcomes. Therefore we will strictly include patients with
a renal mass who are planned for radical nephrectomy.
All inclusions will be reviewed for safety and eligibility by
a nephrologist participating in the research project. The
inclusion and exclusion criteria for this study are listed in
Table 1.
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Core biopsy (standard treatment) Percutaneous renal
core biopsy will be performed directly before the IRE
procedure, utilizing the procedural anaesthesia. A mini-
mum of two percutaneous core biopsies will be har-
vested for pathological examination. In the Academic
Medical Center Amsterdam all patients presented with a
renal mass on cross-sectional imaging, suspicious for
malignancy, are advised to undergo renal core biopsies.
IRE ablation (study intervention) This study utilizes
the Angiodynamics (Queensbury, New York) NanoKnife™
IRE device (Figure 2A), also registered as the HVP-01
Electroporation System. This IRE system consists of a
Low Energy Direct Current (LEDC) generator, footswitch
and 19G monopolar needle electrodes (15 or 25 cm
length). The device and electrodes have been developed
for soft tissue ablation. Both the device and the elec-
trodes carry a CE certificate for cell membrane electro-
poration. The system has been approved by the FDA
via 510(k) Premarket Notifications (K060054, K080202,
K080376, K080287). All 510(k) cleared components are
indicated for surgical ablation of soft tissue.
The IRE procedure will take place at the Radiology de-
partment CT-room under general anaesthesia with muscleFigure 2 IRE equipment. The NanoKnife IRE console (A) utilizes 19G mon
external spacers (C).relaxation, as described by Nielsen et al. [25]. An inter-
ventional radiologist accompanied by a urological sur-
geon will perform the procedure. ECG monitoring and
synchronization of IRE pulses will be performed under
anaesthetic supervision. Needle electrodes (Figure 2B) will
be placed under ultrasound and CT guidance using exter-
nal spacers (Figure 2C) for fixation during pulse adminis-
tration. Probe number and placement will be adjusted for
specific tumour size or targeted tissue ablation in case of
clinical tumor stage ≥ cT1b. Currently practiced IRE set-
tings for tumour ablation are electrode spacing of 15 mm,
electrode tip exposure of 15 mm, 90 pulses of 90 μs (syn-
chronised with ECG) and a pulse intensity of 1500 V/cm.
The IRE treatment cycle will take 5–10 minutes; total
operating time is estimated at 90 minutes. If deemed clin-
ically fit, patients will be discharged 24 hours after the IRE
procedure. Post procedural pain will be quantified at
4 hours, 24 hours and 1 week by means of VAS score,
cumulative opiate use and patient satisfaction.
CEUS and MRI imaging (study intervention) CEUS
and MRI imaging will take place at baseline, one week and
four weeks after IRE ablation in order to assess lesion size
and enhancement. Furthermore, this will reveal possible
complications and any unexpected abnormalities as aopolar needle electrodes (B) which can be locked together using
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gery (radical nephrectomy).
Contrast enhanced ultrasound (CEUS) utilizes a con-
trast agent to increase echogenicity of blood for better
visualisation tissue vascularisation. Ultrasound contrast
contains 3–5 μm microbubbles surrounded by a phospho-
lipid shell. Early studies have shown promising results for
the use of CEUS in the follow-up after cryoablation [26].
This study uses a Philips iU22 (Philips Healthcare, Bothell,
USA) ultrasound device which is optimised for contrast
studies, in combination with SonoVue (Bracco, Milan,
Italy) a third generation ultrasound contrast agent with a
elimination half-life of 6 min [27].
MRI will be performed using a Siemens Avanto 1.5 Tesla
MRI scanner (Siemens Healthcare, Erlangen, Germany)
with a 16-channel body array coil. The MRI protocol will
include at least the following sequences: T2-trufi with fat
suppression, T1-fl2d contrast enhanced in and out of
phase, T2-haste, T1 vibe unenhanced and dynamic series
at 30 seconds, 60 seconds, and 15 minutes. As MRI
contrast agent Gadovist 1.0 (Bayer Pharma, Leverkusen,
Germany) will be used.
Radical nephrectomy (standard treatment) Radical
nephrectomy will be performed four weeks after renal IRE
ablation, either open or laparoscopic depending on patient
specific factors such as co-morbidities and tumour charac-
teristics. It will be performed according to department
protocol by two experienced urologic surgeons.
Sample size
This is a phase 2A (IDEAL), pilot study. In ablation
of renal masses, location and size of the renal mass
influence treatment variables: number of probes and
device settings. The sample size of 10 patients was
chosen in order to explore 2–3 probe configurations.
In this phase of research, this requires at least 3 repe-
titions of a specific probe configuration in order to
assess consistency and the potential influence of otherTable 2 Potential risks associated with IRE of renal tumours
Potential hazards of renal IRE ablation Potential effects
Excessive energy delivery Muscle contraction,
bradycardia/hypoten
stroke, death
Insufficient/no energy delivery Ineffective ablation,
Unintended mains or patient circuit voltage exposure
to patient or user
Electrical shock
Incorrect timing of pulse delivery Transient arrhythmia
Unintended interference with implanted devices
containing electronics or metal parts
Myocardial infarction
Unexpected movement of the device and
displacement of the electrodes
Hypotension, damag
haemorrhage, unint
Sterile barrier breach Infection, sepsisfactors (tumor location, tissue composition) on ablation
volume. Furthermore, a recently published animal study
by Sommer et al. demonstrated a successful evaluation of
CT imaging versus histological analysis with 3 probe con-
figurations using a sample size of 10 cases [28]. A sample
size of 10 patients, testing 2–3 IRE probe configurations,
does not allow for reliable statistical analysis. We will
therefore confine our results to averages and standard
deviations of the assessed volumetric data.
Potential benefits and risks
There are no benefits for patients that participate in this
study. Study participants will be exposed to additional
risk when compared to standard treatment. They will
have to undergo an additional procedure under general
anaesthesia with muscle relaxation. An independent ex-
pert, assigned by the IRB, has estimated the exposure to
ionizing radiation during the IRE procedure at 32 mSv.
IRE is a new tissue ablation technology and IRE of
renal tumours has only been tested in a limited number
of patients. It might be that certain risks and side effects
are unforeseen at this point in time. Potential risks asso-
ciated with IRE for renal tumours, using the NanoKnife™
system, are listed in Table 2. In addition, it is not
expected that renal IRE in patients with ERDS will result
in an acute dependence on dialysis. Both animal and hu-
man studies did not show a substantial decrease in GFR
following renal IRE ablation. Research among patients
suffering from renal insufficiency has however not yet
been conducted. Therefore the possibility of a decrease
in renal function leading to the need for dialysis cannot
be completely excluded.
Data safety monitoring board
The study will be monitored by a data safety monitoring
board (DSMB) consisting of an independent urologist
and a statistician. This team will monitor patient safety
and treatment efficacy data during the study. Monitoring
procedures are predetermined and described in theburn, damage to critical anatomical structure, unintended tissue ablated,
sion, vagal stimulation/asystole, electrical shock, myocardial infarction,
no ablation
, prolonged arrhythmia, stroke, death
, stroke, death
e to critical anatomical structure, pneumothorax, mechanical perforation,
ended tissue ablated, electrical shock, death
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Medical Center, Amsterdam. Additional DSMB meetings
can be called at any time if deemed necessary by the
DSMB or the Principal Investigator.Analysis
The NanoKnife console provides 2D images displaying a
cross section of the predicted ablation zone perpendicu-
lar to the needle tract. Using the AMIRA software pack-
age (FEI Visualisation Sciences Group, Burlington, USA)
the 2D ablation zone cross sections will be stacked along
the length of the exposed electrode tip providing
predicted:
 3D reconstruction
 ablation zone shape/symmetry
 ablation zone volume (cm3)
Pathological examination of the resected specimen will
be performed by an experienced genitourinary patholo-
gist. Prior to the study specific pathology protocol, suffi-
cient material is acquired for routine renal tumour
examination. The kidneys will be cut in a coronal plane
creating 3–4 mm slices. After macroscopic inspection,
the whole IRE lesion will be excised and embedded for
sectioning and staining. Stains to be used will include
hematoxylin and eosin (H&E), nicotinamide adenine di-
nucleotide (NADH) diaphorase and terminal deoxynu-
cleotidyl transferase dUTP nick end labelling (TUNEL).
NADH staining confirms cell viability and TUNEL stain-
ing conversely indicates cell non-viability. Combining
the results of these stains will provide a detailed analysis
of cell viability within the IRE ablation zone.
Microscopic examination will assess:
 IRE ablation volume (cm3)
 ablation zone shape/symmetry
 transition zone
 viable cells within ablation zone
 skip lesions
 damage to blood vessels
 damage to the collecting system
 damage to the renal pelvis
The pathology slides will be digitized using a Ventana
iScan HT pathology slide scanner (Roche, Tuscon, USA).
A 2D reconstruction of the segmented tumour will be
constructed using Fiji (ImageJ). Within the 2D recon-
struction the ablation zone will be outlined. Using the
AMIRA software package the 2D tumour sections will
be stacked to render a 3D reconstruction of the histo-
pathology. This reconstruction is used to assess the
exact lesion volume and shape.MRI and CEUS imaging will be analysed by a specia-
lised urologic radiologist focussing on:
 ablation volume (cm3)
 ablation zone shape/symmetry
 residual tumour on ablation zone border
 skip lesions within ablation zone
 transition zone between ablated and normal renal
tissue
 damage to vital structures
Within the CEUS images basic measurements will be
performed. Within in the MRI images the ablation zone
and the kidney as a whole will be outlined. Using the
AMIRA software package the outlined MRI images will
be stacked to render a 3D reconstruction of the kidney
and the IRE ablation zone within.Discussion
Before progressing to follow-up studies of IRE in renal
masses it is vital to perform tissue specific testing of IRE
ablation efficacy and safety. This trial will investigate IRE
ablation efficacy by comparing 3D histopathological
examination of a (partially) resolved IRE lesion, through
radical nephrectomy with 1) examination of 3D imaging
using MRI and CEUS and 2) 3D prediction of ablation
volume as given by the manufacturer. IRE ablation vol-
ume and shape is influenced by many variables such as
needle number, needle configuration, and device/pulse
settings. With only 10 IRE ablations it is not within in
the scope of this study to experiment with a wide variety
of IRE settings. We aim to test 2 needle electrode con-
figurations, while keeping the device settings constant.
In clinical practice contrast enhanced CT scanning is
most widely used modality for follow-up after renal mass
treatment. In this study however it was decided not to
investigate CT imaging in order to limit the cumulative
radiation exposure. Study participants are already receiv-
ing an estimated 32 mSv of ionizing radiation due to the
CT guided IRE procedure. Adding CT follow-up to the
research protocol would result in 2–3 additional 4 phase
CT scans, besides any CT scans that are necessary after
the final treatment. Another limitation of this study is
the follow-up period, which is limited at 4 weeks. Ani-
mal trials have shown renal IRE lesions to be partially
resolved at 3–4 weeks [20-22]. Preferably radical neph-
rectomy would be postponed longer than 4 weeks, giving
the IRE lesion more time to mature, allowing for better
analysis of intermediate ablation results. However, fur-
ther prolonging the final treatment is unethical at this
early phase of the research. A final limitation is the
tumour size. Patients who are candidate for radical neph-
rectomy, except for patients with ERDS, will have tumours
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tumours ≤ 4 cm, which means that we not testing renal
IRE in the intended population. The choice for radical
nephrectomy was made out of the concern that IRE abla-
tion might complicate a subsequent partial nephrectomy
leading to impaired surgical outcome. In our opinion this
trial will provide essential knowledge on IRE of renal
masses, guiding future research of this promising ablative
technique.
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